Reuters logo
BRIEF-22nd century receives guidance from FDA on phase III clinical trials of co's x-22
2017年6月22日 / 下午2点19分 / 3 个月前

BRIEF-22nd century receives guidance from FDA on phase III clinical trials of co's x-22

June 22 (Reuters) - 22nd Century Group Inc :

* 22Nd century receives guidance from FDA on phase III clinical trials

* Company plans to commence phase III trials for “x-22” smoking cessation product in 2018

* FDA/CDER, co to work to reach deal on design, implementation of two parallel, phase III clinical trials to be conducted by co in parts of U.S. Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below